---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-214186"
form_type: "8-K"
ticker: "VOR"
cik: "0001817229"
company_name: "Vor Biopharma Inc."
filed_at: "2024-09-05T23:59:59+00:00"
generated_at: "2026-05-31T06:17:35.910398+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vor Bio reports positive trem-cel + Mylotarg data; plans pivotal trial

## Summary
- Phase 1/2 VBP101: 18 patients received trem-cel; 10 received Mylotarg as of July 19, 2024 cut-off.
- 100% engraftment (median 9 days); CD33 editing efficiency median 89%; full myeloid chimerism at Day 28.
- Shielding maintained neutrophil/platelet counts across Mylotarg doses 0.5, 1, 2 mg/m^2.
- Early relapse-free survival benefit vs high-risk AML comparators; only 4 relapses recorded.
- New preclinical ADC VADC45 targeting CD45; IND-enabling studies planned; FDA pivotal trial discussion by year-end.

## SEC filing metadata
- accession: 0001193125-24-214186
- form_type: 8-K
- ticker: VOR
- cik: 0001817229
- company_name: Vor Biopharma Inc.
- filed_at: 2024-09-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817229/000119312524214186/0001193125-24-214186-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817229/000119312524214186/d867599d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-214186
- JSON: https://secwatch.observer/filing/0001193125-24-214186.json
- Plain text: https://secwatch.observer/filing/0001193125-24-214186.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.